JP2024533309A5 - - Google Patents
Info
- Publication number
- JP2024533309A5 JP2024533309A5 JP2024515065A JP2024515065A JP2024533309A5 JP 2024533309 A5 JP2024533309 A5 JP 2024533309A5 JP 2024515065 A JP2024515065 A JP 2024515065A JP 2024515065 A JP2024515065 A JP 2024515065A JP 2024533309 A5 JP2024533309 A5 JP 2024533309A5
- Authority
- JP
- Japan
- Prior art keywords
- binds
- pharmaceutically acceptable
- acceptable salt
- protein
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241914P | 2021-09-08 | 2021-09-08 | |
| US63/241,914 | 2021-09-08 | ||
| US202163293591P | 2021-12-23 | 2021-12-23 | |
| US63/293,591 | 2021-12-23 | ||
| US202263351639P | 2022-06-13 | 2022-06-13 | |
| US63/351,639 | 2022-06-13 | ||
| US202263374282P | 2022-09-01 | 2022-09-01 | |
| US63/374,282 | 2022-09-01 | ||
| PCT/IB2022/058428 WO2023037268A1 (en) | 2021-09-08 | 2022-09-07 | Linkers for use in antibody drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533309A JP2024533309A (ja) | 2024-09-12 |
| JP2024533309A5 true JP2024533309A5 (OSRAM) | 2025-09-17 |
Family
ID=85506299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515065A Pending JP2024533309A (ja) | 2021-09-08 | 2022-09-07 | 抗体薬物複合体に使用するためのリンカー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250144230A1 (OSRAM) |
| EP (1) | EP4398942A1 (OSRAM) |
| JP (1) | JP2024533309A (OSRAM) |
| KR (1) | KR20240067085A (OSRAM) |
| AU (1) | AU2022344582A1 (OSRAM) |
| CA (1) | CA3231039A1 (OSRAM) |
| IL (1) | IL311231A (OSRAM) |
| MX (1) | MX2024002862A (OSRAM) |
| TW (1) | TW202330037A (OSRAM) |
| WO (1) | WO2023037268A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024151547A1 (en) | 2023-01-09 | 2024-07-18 | Monte Rosa Therapeutics, Inc. | Targeted degradation of vav1 |
| WO2024238872A2 (en) * | 2023-05-18 | 2024-11-21 | Firefly Bio, Inc. | Isoindolinone-glutarimide antibody conjugates, and uses thereof |
| CN121568925A (zh) | 2023-07-25 | 2026-02-24 | 蒙特罗莎治疗股份有限公司 | 用于靶向蛋白质降解的取代的哌啶二酮 |
| AU2024339843A1 (en) | 2023-09-13 | 2026-04-23 | Astellas Pharma Inc. | Antibody-drug conjugate containing heterocyclic compound having G12D mutant KRAS protein degradation-inducing effect |
| WO2025146112A1 (en) * | 2024-01-05 | 2025-07-10 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Gspt1 degrading compounds and compositions and uses thereof |
| WO2025189204A2 (en) * | 2024-03-08 | 2025-09-12 | Inmune Bio Inc. | Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization |
| WO2025221780A1 (en) * | 2024-04-16 | 2025-10-23 | Genzyme Corporation | Salts of irak4 degrader |
| WO2025228381A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugate and use thereof |
| WO2026013576A1 (en) | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Dihydrouracil derivatives useful for the targeted degradation of vav1 |
| WO2026013577A1 (en) | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026052637A1 (en) | 2024-09-03 | 2026-03-12 | Monte Rosa Therapeutics Ag | Targeted protein degradation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358697B1 (en) * | 2008-10-29 | 2015-10-21 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer. |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP2022553932A (ja) * | 2019-10-18 | 2022-12-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 薬物複合体形成の部位特異的な定量化の方法 |
-
2022
- 2022-09-07 TW TW111133968A patent/TW202330037A/zh unknown
- 2022-09-07 AU AU2022344582A patent/AU2022344582A1/en active Pending
- 2022-09-07 MX MX2024002862A patent/MX2024002862A/es unknown
- 2022-09-07 JP JP2024515065A patent/JP2024533309A/ja active Pending
- 2022-09-07 KR KR1020247011575A patent/KR20240067085A/ko active Pending
- 2022-09-07 CA CA3231039A patent/CA3231039A1/en active Pending
- 2022-09-07 IL IL311231A patent/IL311231A/en unknown
- 2022-09-07 US US18/690,506 patent/US20250144230A1/en active Pending
- 2022-09-07 WO PCT/IB2022/058428 patent/WO2023037268A1/en not_active Ceased
- 2022-09-07 EP EP22866845.5A patent/EP4398942A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519974A5 (OSRAM) | ||
| JP2021501570A5 (OSRAM) | ||
| JP2021530243A5 (OSRAM) | ||
| JP2019502746A5 (OSRAM) | ||
| JP2022511813A5 (OSRAM) | ||
| JP7042291B2 (ja) | リンカー及びａｄｃへのその応用 | |
| JP2022109915A (ja) | Ｃｄ８０バリアント免疫調節タンパク質およびその使用 | |
| IL263616B1 (en) | Antibody adjuvant conjugates | |
| JP7282760B2 (ja) | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| JP2021515599A5 (OSRAM) | ||
| JP2020055828A5 (OSRAM) | ||
| JP2021529516A5 (OSRAM) | ||
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| WO2017091615A1 (en) | Humanized anti-cll-1 antibodies | |
| JP2023513156A5 (OSRAM) | ||
| TW202200619A (zh) | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 | |
| FI4034252T3 (fi) | Saranadomeenin sisältäviä Notch-reseptoreita | |
| US20240181072A1 (en) | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | |
| CN115698088A (zh) | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 | |
| JP2023533218A5 (OSRAM) | ||
| JP2023546725A5 (OSRAM) | ||
| JP2021534769A5 (OSRAM) | ||
| JP2024510900A5 (OSRAM) | ||
| JP2023550148A5 (OSRAM) | ||
| JP2021505637A5 (OSRAM) |